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通过研究 NRP-1mAb 对肝癌 HepG2 细胞株的生长抑制和促凋亡作用及其机





通过小鼠腹水法和 rProteinA 亲和柱纯化等步骤制备 NRP-1mAb。SDS-PAGE 测
定抗体的纯度，BCA 法测定抗体的浓度，间接 ELISA 检测 NRP-1mAb 的滴度水
平。Western blotting 检测 NRP-1mAb 与 HepG2 细胞结合的特异性，细胞免疫荧
光染色和流式细胞术检测 NRP-1mAb 与 HepG2 细胞上 NRP-1 结合的亲和性。
MTT 检测 NRP-1mAb 对 HepG2 细胞的生长抑制作用，ANNEXIN V-FITC/PI 流
式细胞仪法检测 NRP-1mAb 对 HepG2 细胞的促凋亡作用，Western blotting 检测
ERK1/2、P-ERK1/2、Akt、P-Akt、caspase3、PARP、P38-MAPK、P-P38MAPK
蛋白的表达水平。 
动物实验：构建肝癌 HepG2 裸鼠移植瘤模型，当瘤体最大径达到 0.5cm 时,
随 机 分 为 八 组 ： 空 白 对 照 组 ， NRP-1mAb 组 ， rhVEGI-192 组 ，
NRP-1mAb+rhVEGI-192 组，10Gy 组， 10Gy+NRP-1mAb 组，10Gy+rhVEGI-192
组，10Gy+NRP-1mAb+rhVEGI-192 组，每组 8 只。NRP-1mAb 是 10mg/kg 隔天
腹腔给药一次，共 2 周；rhVEGI-192 是 5mg/kg 每天腹腔给药 1 次，共 2 周；照
射组在实验第 9 天用 10Gy 剂量单次照射裸鼠移植瘤部位。隔天测量小鼠体重和
移植瘤的体积，计算照射组的增敏系数（SER）。通过 Western blotting 法检测移
植瘤组织中 HIF-1a、PTEN、caspase3、PARP 蛋白的表达水平；免疫荧光化学染
色法检测移植瘤组织中血管内皮标志物 VE-cadherin、CD31 和 IV 胶原的表达情
况。 
结果： 
体外实验：rhVEGI-192 的纯度超过 90%，浓度为 1.5mg/ml；NRP-1mAb 纯















HepG2 细胞膜上的 NRP-1 蛋白且与它有较强的亲和性；MTT 和 ANNEXIN 
V-FITC/PI 流式细胞仪结果显示 NRP-1mAb 能抑制 HepG2 细胞的生长并能诱导
HepG2 细胞的凋亡，作用呈时间和剂量依赖性。Western blotting 结果显示
P-ERK1/2、P-Akt、caspase3、PARP 蛋白表达下调，P-P38MAPK 蛋白表达上调； 
动物实验：与空白组相比,实验组小鼠体重变化无明显差异，各组移植瘤的
生长受到不同程度的抑制，照射组移植瘤生长被抑制的更明显；10Gy+NRP-1mAb
组 SER 为 0，10Gy+rhVEGI-192 组 SER 为 2，10Gy+NRP-1mAb+rhVEGI-192 组
SER 为 4；Western blotting 结果显示与空白组相比，NRP-1mAb 组，rhVEGI-192
组和 NRP-1mAb+rhVEGI-192 组移植瘤中 HIF-1a、caspase3、PARP 蛋白表达下
调，而 PTEN 蛋白表达上调。免疫荧光化学染色结果显示：空白组肿瘤血管丰富，
曲折，不连续，分支较多，血管粗细不均，基底膜不完整；NRP-1mAb 组的血管
未见明显改善； rhVEGI-192 组移植瘤内的血管在实验第 9-11 天的形态和结构趋
于正常化；NRP-1mAb 联合 rhVEGI-192 组移植瘤内的血管在实验第 7-11 天内的
形态和结构趋于正常化。 
结论： 
1.NRP-1mAb 抑制 HepG2 细胞株的生长是通过下调 MEK/ERK、PI3K/Akt
信号通路来实现的； 
    2.NRP-1mAb 诱导 HepG2 细胞株凋亡是通过上调 P38MAPK-caspase3-PAPR
信号通路来实现的。 
    3.NRP-1mAb、rhVEGI-192 对裸鼠肝癌 HepG2 移植瘤有明显诱导凋亡的作
用，两药联合时促凋亡作用较单药时不明显。 
    4.NRP-1mAb 无放射增敏作用；rhVEGI-192 有放射增敏作用，使肿瘤血管
正常化时间窗是第 9-11天；NRP-1mAb 联合 rhVEGI-192 时具有更强的放射增敏
作用，使肿瘤血管正常化时间窗是第 7-11 天。通过比较各组的 SER 提示
NRP-1mAb 对 rhVEGI-192 具有协同作用。 




















To determine the antiangioenic and antitumor activities of two molecular 
targeted drugs, NRP-1mAb and rhVEGI-192.We investigated the growth inhibition 
and apoptosis effects of NRP-1mAb on hepatocellular carcinoma HepG2 cells and its 
mechanism, and then preliminarily explored the radiosensitivity effect of NRP-1mAb 
combined with rhVEGI-192 on hepatocellular carcinoma HepG2 xenografts in nude 
mice and its mechanism. This may provide a new therapeutic strategy and theoretical 
basis for the clinical treatment of hepatocellular carcinoma. 
Method： 
Experiment in vitro：Recombinant human VEGI-192 was produced in E.coli 
and purified by a nickel column to be apparent homogeneity. NRP-1mAb was 
prepared from mouse ascites and purified by rProteinA affinity column. SDS-PAGE 
and BCA were applied to determine the purity and concentration of antibody 
respectively. Indirect ELISA was used to detect the titer of NRP-1mAb. Western 
blotting, immunofluorescence staining and flow cytometry were applied to detect the 
binding specificity and affinity of the NRP-1mAb with NRP-1 on HepG2 cells. 
Growth inhibitory effect ofNRP-1mAb on HepG2 cells was analyzed by MTT assay. 
ANNEXIN V-FITC/PI flow cytometry was used to detect the apoptosis rates of 
HepG2 cells treated with different concentration NRP-1mAb. The expression levels of 
ERK1/2, P-ERK1/2, Akt, P-Akt, Caspase3, PARP, P38-MAPK and P-P38MAPK 
protein was measured by Western blotting. 
Animal experiment: We constructed a hepatocellular carcinoma HepG2 
xenografts model in nude mice. When the tumor diameter reached 0.5cm, the nude 
mice were randomized and divided into control and treatment groups. The treatment 
groups were given 5mg/kg of rhVEGI-192 once a day or 10 mg/kg of NRP-1mAb 
every other day via intraperitoneal injection for two weeks, the radiotherapy groups 
were irradiated with single dose of 10Gy on the ninth day and the control group were 















other day, and the sensitivity enhancement ratio（SER）was calculated. Western 
blotting detected the expression levels of HIF-1a, PTEN, Caspase3 and PARP 
proteins in transplanted tumor tissues. Immunofluorescence staining was used to 
measure the expression of vascular endothelial markers such as: VE-cadherin, CD31 
and IV collagen in transplanted tumor tissues. 
Results： 
Experiment in vitro：The purity of rhVEGI-192 was higher than 90% and its 
concentration was 1.5mg/ml. The purity of NRP-1mAb was about 95% ,the 
concentration was 2mg/ml and the titer was about 1×10
-6
. NRP-1mAb could 
specifically bind to NRP-1 on HepG2 cell membrane and had strong affinity with it. 
MTT assay and Annexin V-FITC/PI flow cytometry indicated that NRP-1mAb could 
effectively inhibit HepG2 cells growth and induce HepG2 cells apoptosis in a 
time-and dose-dependent manner. Western blotting results showed that P-ERK1/2, 
P-Akt, Caspase3, PARP protein was down regulated and P-P38MAPK protein was 
up-regulated in HepG2 cells treated by NRP-1mAb. 
Animal experiment: Compared with the blank group, mice in the experimental 
group did not suffer weight loss, the growth of the transplanted tumor was inhibited to 
some extent, and the growth inhibition was more obvious in the irradiation group. The 
sensitivity enhancement ratio（SER）of NRP-1mAb+10Gy group, rhVEGI-192+10Gy 
group and rhVEGI-192+NRP-1mAb+10Gy group were 0,2,4. Western blotting results 
showed that compared to the control group, the expression of HIF-1a, Caspase3, 
PARP proteins were down regulated, while PTEN protein was up-regulated in the 
treatment groups transplanted tumor tissue. Immunofluorescence staining indicated 
that tumor vessels in the control group were abundant, tortuous, discontinuity, more 
branches, uneven thickness of lumen and the basement membranes were incomplete. 
The NRP-1mAb group showed no significant improvement in blood vessel. The 
morphology and structure of blood vessels in rhVEGI-192 group tended to normalize 
in ninth to eleventh days, while rhVEGI-192combined with NRP-1mAb group was 
















1.NRP-1mAb inhibited the growth of HepG2 cells by down-regulating the 
MEK/ERK and PI3K/Akt signaling pathway； 
    2.NRP-1mAb induced apoptosis in HepG2 cells by up-regulating the 
P38MAPK-caspase3-PAPR signaling pathway； 
    3.NRP-1mAb and rhVEGI-192 had obvious effect on inducing apoptosis in nude 
mice with HepG2 xenografts ,When the two drugs were combined the apoptosis effect 
was not obvious. 
    4.NRP-1mAb has no radiosensitization effect.rhVEGI-192showed 
radiosensitization effect and its vascular normalization window is 9 to 11 days. When 
NRP-1mAb combined with rhVEGI-192 its normalized time window was 7 to11 days. 
By comparing the SER of each group, the results suggested that NRP-1mAb had 
synergistic effect on rhVEGI-192. 
    5.NRP-1mAb and rhVEGI-192 could increase PTEN and decrease HIF-1a which 
induce to improve hypoxia, normalize blood vessels, inhibit tumor angiogenesis and 
enhance the radiosensitivity of HepG2 xenografts. 
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